Synaffix has announced that it has entered into a licensing agreement with SOTIO Biotech to expand its antibody-drug conjugate (ADC) pipeline in a deal worth up to $740m.

As part of the deal, SOTIO, a clinical-stage immune-oncology company, will gain access to Synaffix’s ADC technologies, GlycoConnect, HydraSpace and toxSYN to advance research and expand commercial licences into two additional programmes at a later date.

All three technologies are designed to enable best-in-class ADCs from any antibody while significantly enhancing efficacy and tolerability.

In combination, the three technologies provide developers with an easy-to-use ADC technology platform, allowing any antibody developer to develop its own ADC and expand its pipeline further.

Under the terms of the agreement, Synaffix will receive up to $740m in payments, including milestone payments as well as additional royalties on commercial sales.

SOTIO will be responsible for the research, development and commercialisation of the ADCs and will develop up to three next-generation bioconjugates.

Synaffix will manufacture the components specifically related to its technologies.
Peter van de Sande, head of Synaffix, said: “The selection of our ADC technologies by a seasoned ADC player like SOTIO is a strong recognition of the potential of these technologies to maximise the therapeutic index of ADCs.

“We look forward to partnering with SOTIO and believe that with their singular focus on cancer immunotherapies and robust clinical pipeline, this partnership can deliver innovative medicines for patients in areas of high unmet medical need.”

Radek Spisek, chief executive officer of SOTIO, said: “At SOTIO, we are building a broad pipeline of next-generation ADCs to address the challenges of solid tumours – and access to Synaffix’s ADC platform technologies will ensure we remain at the leading edge of this space.”

Elligo Health Research has announced it is expanding its IntElligo Study Marketplace platform with Syneos Health.

The platform aims to make sales, site selection and application processes more transparent and efficient for clinical trial sponsors, clinical research organisations and sites, while also tracking progress.

As part of the agreement, Syneos will utilise Study Marketplace to expand access to clinical trials, increase efficiencies for sites and sponsors across over 500 of Elligo’s US site networks and cover a broad range of therapeutic areas.

Launched in 2022 by the healthcare-enabling research organisation, Study Marketplace is a one-stop platform that aims to accelerate participation in clinical research and allows sites to manage their entire pipeline process on a single, user-friendly portal.

Updated in June this year, IntElligo Study Marketplace allows sites to easily access and browse available studies and study documents, apply for those of interest, track progress and collaborate among team members and Elligo throughout the sales cycle.

The expansion builds upon the companies’ existing partnership, announced in 2018, to collaboratively “evolve the clinical trial paradigm” and “speed the delivery of biopharmaceutical therapies to market”.

Elligo will work with biopharmaceutical solutions organisation Syneos “to make study management and clinical research more easily available to all patients,” said chief executive officer of Elligo, John Potthoff.

Terttu Haring, president, clinical sites and patients at Syneos Health, said: “We know sites are stretched thin, so utilising a platform that efficiently allows them to view study opportunities and accelerate the start of the clinical trial process is inherently valuable to optimise customer success and accelerate the development of life-changing therapies worldwide.”